Cancer Res: Study reveals new treatment for melanoma

February 2, 2021 /--- The treatment of melanoma has come a long way in the past five years, however, even with these treatments, many patients can quickly develop resistance and die from the disease.
new study from Boston University School of Medicine (BUSM) found that drugs previously developed for a specific type of protein (YK-4-279) have a wide range of uses for protein families that promote melanoma.
"We found that the drug inhibits melanoma in human cells and experimental models.
We also found a specific way for the drug to fight cancer: proteins associated with inhibiting the genetic coding that drives cancer cell growth and metastasis," explained co-author Dr. Deborah Lang, an associate professor of dermatology at BUSM.
(Photo: www.pixabay.com) melanoma is a malignant cancer with a high tendency to attack and metastopion early in the disease process.
factors that actively contribute to the progression of melanoma include MET, a tyrosine kinase complex that is over-expressed in melanoma and is associated with tumor growth, invasion and drug resistance.
researchers used human cells in culture to determine whether there had been significant changes in precancerote behavior in these cells with or without the drug YK-4-279, and found a significant decrease in the growth and movement of cancer cells after the use of the drug.
, the experimental model treated with the drug has been significantly delayed or has not progressed to an invasive disease.
researchers believe the findings provide an opportunity for YK-4-279 to become an option for melanoma treatment, available alone or in combination with other available therapies.
"We found that the molecule disrupts the interaction of two known factors that regulate melanin cells and promote melanoma through gene regulation."
work may affect other systems in which it works, such as nervous system and pigment abnormalities.
Bioon .com source: Researchers identifying agent agent against melanoma Original source: Lee Huang et al, Targeting pan-ETS factors reseds melanoma progression, Cancer Research (2021). DOI: 10.1158/0008-5472.CAN-19-1668